Teva Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Pharma (TEVA) Tops Q2 EPS by 14c; Raises Outlook
August 2, 2018 7:02 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $0.78, $0.14 better than the analyst estimate of $0.64. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.74 billion.
GUIDANCE:
Teva Pharma sees FY2018 EPS of $2.55-$2.80, from $2.40-$2.65 and... More
